| 47.57 -0.99 (-2.04%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 59.45 | 1-year : | 69.43 |
| Resists | First : | 50.9 | Second : | 59.45 |
| Pivot price | 46.6  |
|||
| Supports | First : | 38.03 |
Second : | 30.09 |
| MAs | MA(5) : | 48.47 |
MA(20) : | 44.67 |
| MA(100) : | 29.23 |
MA(250) : | 21.91 |
|
| MACD | MACD : | 4 |
Signal : | 4.2 |
| %K %D | K(14,3) : | 76.4 |
D(3) : | 81.4 |
| RSI | RSI(14): 66.8 |
|||
| 52-week | High : | 50.9 | Low : | 12.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PLSE ] has closed below upper band by 39.9%. Bollinger Bands are 14.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 49.05 - 49.32 | 49.32 - 49.54 |
| Low: | 46.27 - 46.65 | 46.65 - 46.96 |
| Close: | 47.01 - 47.57 | 47.57 - 48.03 |
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Fri, 28 Aug 2026
PLSE | Pulse Biosciences, Inc Common Financials - Income Statement - Quiver Quantitative
Fri, 28 Aug 2026
Pulse Biosciences (PLSE) COO buys stock in two August trades - Stock Titan
Fri, 28 Aug 2026
Pulse Biosciences (NASDAQ: PLSE) COO listed as insider with no stake disclosed - Stock Titan
Fri, 28 Aug 2026
Pulse Biosciences (NASDAQ: PLSE) links CFO options to value and revenue goals - Stock Titan
Tue, 18 Aug 2026
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Sun, 16 Aug 2026
Pulse Biosciences (PLSE) Is Up 5.0% After Wider Losses And $75M ATM Plan Filed – Has The Bull Case Changed? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 2.059e+007 (%) |
| Held by Institutions | 71 (%) |
| Shares Short | 2,860 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.262e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 823 % |
| Return on Equity (ttm) | -44.4 % |
| Qtrly Rev. Growth | 1.19e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -49.68 |
| EBITDA (p.s.) | 1898.73 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.96 |
| Price to Cash Flow | 53.68 |
| Dividend | 0 |
| Forward Dividend | 2.98e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|